Exhibit 99.1 Neurocrine Biosciences Reports First-Quarter 2026 Financial Results Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Net Product Sales Highlights Recent Clinical and Corporate Developments • Total first-quarter 2026 net product sales were $811.0 million, representing 44% growth year-over-year. • INGREZZA first-quarter 2026 net product sales were $656.9 million, representing 20% growth year-over- year. Results reflected double-digit prescription vol ...